The most successful ACT-based immunotherapy for solid tumors is the transfusion of TILs in metastatic melanoma patients [42, 45] together with lymph-depletion conditioning and administration of IL-2; however, the application of TILs to CRC is limited because of the absence of tumor-specific effector cells after ex vivo expansion [46]. The gene discussed is IL2; the disease is colorectal carcinoma.